Clinuvel Pharmaceuticals Limited (ASX: CUV)
Australia
· Delayed Price · Currency is AUD | Market Cap | 588.87M |
| Revenue (ttm) | 88.18M |
| Net Income (ttm) | 35.64M |
| Shares Out | 49.95M |
| EPS (ttm) | 0.70 |
| PE Ratio | 16.89 |
| Forward PE | 16.46 |
| Dividend | 0.05 (0.42%) |
| Ex-Dividend Date | Sep 5, 2024 |
| Volume | 121,073 |
| Open | 12.00 |
| Previous Close | 11.94 |
| Day's Range | 11.72 - 12.00 |
| 52-Week Range | 11.72 - 17.71 |
| Beta | 0.92 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 19, 2025 |
About Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900 and Parvysmelanotide (VLRX001), both alpha-melanocyte stimulating h... [Read more]
Financial Performance
In 2024, Clinuvel Pharmaceuticals's revenue was 88.18 million, an increase of 12.59% compared to the previous year's 78.32 million. Earnings were 35.64 million, an increase of 16.44%.
Financial StatementsNews
Lady Gaga portends ASX pay blushes
Clinuvel Pharmaceuticals CEO Philippe Wolgen sidles up to celebrities before shareholders ding his generous pay.
CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP
MELBOURNE, Australia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- CLINUVEL has filed a New Drug Submission (NDS) to Health Canada, seeking approval for its novel photoprotective therapy SCENESSE® (afamelanotide...
Clinuvel Pharmaceuticals Limited (CLVLY) Q4 2024 Earnings Call Transcript
Clinuvel Pharmaceuticals Limited 2024 Q4 - Results - Earnings Call Presentation
Clinuvel Pharmaceuticals GAAP EPS of A$0.72, revenue of A$96.3M
Afamelanotide in fair-skinned Parkinson's patients
MELBOURNE, Australia, June 18, 2024 (GLOBE NEWSWIRE) -- CLINUVEL today announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson's Disease (PD or Parkinson's)...
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide...
Malibu shines a light on CLINUVEL's pioneering work in photomedicine
MALIBU, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Leading biotech company CLINUVEL last week joined an intimate event bringing together California's most prolific investors and philanthropists at the...
Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2023 Earnings Call Transcript
Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2023 Earnings Call Transcript
CLINUVEL Launches CYACÊLLE, Next Generation Solar Care
UV, HEV protection for individuals at high risk of photoageing and skin cancer
Global SCENESSE® demand drives increased CLINUVEL revenues, earnings
MELBOURNE, Australia, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Executive summary Positive Results in the Half Year to 31 December 2022
CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals
Study in healthy volunteers shows single dose of afamelanotide reduces erythema caused by ultraviolet radiation Study in healthy volunteers shows single dose of afamelanotide reduces erythema caused b...
CLINUVEL Trial Results Show Drug Reduces DNA Damage
Results in “children of the moon” disorder have implications for populations at highest risk of skin cancer Results in “children of the moon” disorder have implications for populations at highest risk...
CLINUVEL progresses vitiligo treatment program
Novel approach to addressing pigment loss disorder affecting an estimated 45 million individuals worldwide Novel approach to addressing pigment loss disorder affecting an estimated 45 million individu...
Positive final results in stroke
World-first stroke study CUV801 evaluating afamelanotide World-first stroke study CUV801 evaluating afamelanotide
Letter to shareholders from CLINUVEL's CEO
LONDON, April 29, 2022 (GLOBE NEWSWIRE) -- Dear shareholders, friends,
Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2022 Results - Earnings Call Transcript
Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2022 Results - Earnings Call Transcript
CLINUVEL Expands Pharmaceutical Portfolio
Melanocortin drug NEURACTHEL® (ACTH) added for neurological, endocrinological and degenerative disorders Melanocortin drug NEURACTHEL® (ACTH) added for neurological, endocrinological and degenerative ...
CLINUVEL expands DNA Repair Program
SCENESSE® (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V)
Clinuvel: Stroke And DNA Repair Unlock Large New Markets
Clinuvel Pharmaceutical has introduced its first commercial product “Scenesse” in Europe and the US in 2014 and 2019 for the rare disease “EPP”. Since then, it has stayed very secretive about its futu...
Clinuvel publishes its long-awaited Strategic update
Clinuvel Pharmaceutical has introduced its first commercial product “Scenesse” in Europe and the US in 2014 and 2019 for the rare disease “EPP”. Since then, it has stayed very secretive about its futu...